On this page

New application for authority Forms

NSW Health is committed to improving the efficiency of regulation and monitoring of controlled medicines.

To achieve this, NSW Health has introduced new authority application forms. These new forms are quicker to complete and require less information and supporting documentation from prescribers.

The new application forms are pdf fillable and can be accessed on the NSW Health website. In the initial period following release of the new forms, both new and old forms will be accepted. From 1 February 2023 old application forms will no longer be accepted.
NSW Health is also developing a new online system to manage authority applications which will be available in 2023. The new system will allow prescribers to submit authority applications online, track progress of their applications and in some cases, receive approvals in real time. It will also provide Pharmaceutical Regulatory staff with an improved system for the management and approval of authorities, helping to reduce the turnaround time for applications.

If you have any questions or would like to provide feedback on the new application forms, please email 

Updated pharmaceutical regulatory guidelines for prescribing or supplying psychostimulants in attention deficit hyperactivity disorder (ADHD)

Updated guidelines outlining the requirements for obtaining authorisation to prescribe or supply psychostimulants for ADHD in children, adolescents and adults have been released. These guidelines have been revised to align with the release of new authority application forms and can be accessed on the NSW Health website or from the links below

PDF Criteria for the Management of Medication for Attention Deficit Hyperactivity Disorder in Children and Adolescents (TG181)

PDFCriteria for the Management of Medication for Attention Deficit Hyperactivity Disorder in Adults (TG190)


Date of birth on prescriptions and in dispensing records

From 1 November 2022 all prescriptions for Schedule 4 and Schedule 8 medicines, including handwritten and computer-generated prescriptions, must include the patient’s date of birth. The dispensing pharmacist must make a record of the date of birth in the dispensing system when dispensing the medicine.

Special temporary authority for emergency supply without a prescription

A special temporary authority to allow the pharmacist to supply prescription medicines (other than Schedule 4 Appendix D and Schedule 8 medicines) during the COVID-19 pandemic is in place until 1 February 2023.

Refer to supply of prescription medicines for valid prescription formats.

State-wide pilot for appropriately trained community pharmacists to prescribe medications

On 13 November 2022, the NSW Government announced its commitment to:

  • commence a 12-month clinical trial to evaluate allowing appropriately trained pharmacists to prescribe medication for urinary tract infections; and
  • progress a state-wide pilot where appropriately trained pharmacists can prescribe medications for a range of minor conditions, in consultation with pharmacy regulators.
For more information refer to Community pharmacy state-wide pilot


Nicotine vaping products

Consumers require a prescription to be supplied with nicotine vaping products, such as nicotine e-cigarettes, nicotine pods and liquid nicotine.

The TGA has not approved any nicotine vaping products for supply in Australia. Pathways for access to these unapproved therapeutic goods are the:

  • Authorised Prescriber Scheme
  • Special Access Scheme
  • Personal Importation Scheme

For more information, refer to Nicotine vaping.

Serious scarcity medicine substitution

In some circumstances it is legal for a retail pharmacist to substitute different strengths or formulations of a prescribed medicine, without contacting the prescriber.

Where there is a Serious Scarcity Substitution Notice on the TGA website, substitution is permitted if it is appropriate and the patient consents. The notice will specify which products may be substituted and the specific circumstances it may be substituted.

Under Part 4A of the NSW Poisons and Therapeutic Goods Act 1966, pharmacists must comply with all provisions of the relevant Commonwealth Serious Scarcity and Substitutable Medicine Instrument.

For information on subsidy under the Commonwealth Pharmaceutical Benefits Scheme, visit the PBS website.

Free take home naloxone - Australian Government pilot program

NSW is participating in the Australian Government take home naloxone pilot which supplies take home naloxone free of charge to people who may experience, or witness, an opioid overdose.

Nyxoid® nasal spray and Prenoxad® pre-filled syringe are available for free without a prescription at:

Outside of the pilot, naloxone is also available on a doctor's prescription or over the counter from a community pharmacist.

Approval for use of an Electronic National Residential Medication Chart (eNRMC)

The Commonwealth PBS transitional arrangements for use of an electronic National Residential Medication Chart (eNRMC) is under the National Health (Electronic National Residential Medication Chart Trial) Special Arrangement 2018. Only the residential care facilities (RCF) and community pharmacies in the Schedule of the Special Arrangement may use the respective eNRMC in the Schedule.

Use of the eNRMC must comply with the National Health (Electronic National Residential Medication Chart Trial) Special Arrangement 2018. Only the RCFs and community pharmacies in the Schedule of the Special Arrangement may use an eNRMC.

Under exemptions to the NSW Poisons and Therapeutic Goods Regulation 2008 electronic prescribing on an eNRMC can be used:

  • as a form of prescription for pharmacist dispensing
  • as a form of medication chart order to direct administration by RCF staff.

This applies to all medicines prescribed for RCF residents (that is, PBS and non-PBS).

Current as at: Tuesday 29 November 2022
Contact page owner: Pharmaceutical Services